Big week ahead for #AVCT! π
Investor meetings all week, followed by the AVA6207 presentation on Thursday.
Where do people see Avactaβs share price this time next week?
60p, 75p, Β£1+ or somewhere else?
Interested to hear your predictions! π
@RAH00084 Interesting point RAH. π Trumpβs administration has been pushing the FDA to accelerate innovative drug development and approvals. Given AVA6103βs promising early safety and PK data, could an FDA Fast Track application be on Avactaβs radar? #AVCT π
#AVCT With AVA6207's payload identities potentially being revealed on 19 November, here's a question.
If the ATR inhibitor belongs to a major pharmaceutical company, do you think that company could become an Avacta partner? π
#AVCT What a turnaround from yesterday! π Buyers stepping in, volume picking up and momentum improving. Can we push through that final hurdle and close at 60p or above today? ππ
#AVCT When Avacta expressed excitement about AVA6207, management almost certainly already knew the key results being presented on 19 November.
The science hasn't deteriorated just because the SP has fallen.
Whoever is selling at 52p, it doesn't prove they know bad news. π
#AVCT With AVA6207's payload identities potentially being revealed on 19 November, here's a question.
If the ATR inhibitor belongs to a major pharmaceutical company, do you think that company could become an Avacta partner? π
Buying #AVCT on a pump & it's soaring feels great - but you are exit liquidity. That is the moment of highest risk, yet it feels so safe.
Selling now: you're ENTRY liquidity. There's a FIGHT for your shares. Somebody knows what's coming. An 8x from Β£1, is now 15x from here.
#AVCT So much for 55p being the bottom! Already testing 53p this morning, yet sizeable buys are appearing at these levels. Is a large seller still unloading, or are buyers finally absorbing the stock? The science keeps progressing, but the SP tells a very different story.
@TonyRob70579912@SeanDentBsc@tom_the_bomb__#AVCT AVA6207 isn't being developed because AVA6103 has failed. It's a planned extension of pre|CISION. The science is progressing across multiple programmes, but Tony has a fair point: sooner or later, Pharma interest needs to translate into a meaningful commercial deal.
#AVCT The SP keeps falling, yet the science continues to progress. Large trades at 55β56p suggest serious activity, but who's buying and selling remains unclear. With AVA6207 news and AVA6103 tumour data ahead, will the market finally start valuing the potential?
@AndrewDigby3@AndrewDigby3 Interesting! Iβve checked the LSEG files and confirmed the earlier large off-exchange trades. Can you share where youβre seeing the 4.5m OTC trade at 16:03, or post a screenshot? Would be good to verify whether itβs one transaction or several aggregated. #AVCT
Interesting $AVCT trades today. LSEG confirms 3 off-exchange reports at 56p: 779,355 twice and 1,120,645 shares. The identical trades have different IDs but may be dual reports. Potentially 1.9m shares (Β£1.064m). Institutional transfer or short covering? Unconfirmed. #AVCT
@Gear_Tales@AM231982 Durable responses and tolerability matter, agreed. But dismissing the progress overlooks AVA6103's clinical proof of mechanism and the responses already seen with AVA6000. Risks remain, of course, but the science has moved forward significantly. #AVCT
@Mike182035 I see your point now Mike. You're looking at corporate moves rather than just the science. Makes sense with the funding clock ticking. A licensing or carve-out deal before year-end would be very welcome. Something tangible commercially could restore shareholder confidence. #AVCT
#AVCT The science is increasingly compelling. AVA6000 showing human efficacy signals, AVA6103 clinical proof of mechanism and AVA6207 promising preclinical results. Now it's time for commercial validation. How much more evidence does Big Pharma need before committing to a deal?
#AVCT The science keeps progressing, yet the SP remains stuck around 57p despite encouraging clinical data. The market wants more than scientific progress now. It wants commercial validation and funding certainty. A meaningful Pharma deal could change that picture overnight.